JSR Life Sciences announced that KBI Biopharma, Inc. (KBI) and Selexis SA are consolidating as one organization under the KBI Biopharma name to accelerate innovation and growth for its global biopharma customers.

According to JSR, the new structure will enable integrated, seamless solutions for customers, cell line development through process development, to clinical and commercial cGMP manufacturing services for mammalian programs.

The streamlined operational approach supports customers in rapidly accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. Bringing together the capabilities and expertise of KBI Biopharma and Selexis aims to reduce manufacturing risks for customers.

“The fusion of KBI and Selexis as one business advances KBI into an exciting strategic growth phase,” said Tim Lowery, President of JSR Life Sciences. “This natural operational strategy shift is pivotal for KBI and Selexis customers that count on the wide range of capabilities and services to accelerate their evolving manufacturing and drug development needs.”

The combined organization will leverage the collective knowledge, scientific expertise, and industry-leading technical acumen of KBI as an important part of the entire JSR Life Sciences ecosystem. Reorganizing and simplifying the operating model aims to offer a seamless experience and expedite innovation for KBI’s global clients.

“The operational consolidation of these two exceptional companies represents a major shift in how KBI Biopharma will operate moving forward,” said J.D. Mowery, CEO of KBI Biopharma. “By providing fully integrated solutions for our customers, we will be a stronger partner that can help them each reach their goals more efficiently.”

Selexis’ proprietary cell line development platform will be branded as the SUREtechnology Platform. Mowery will be the CEO of the combined organization.